Femara 2.5 Mg 30 Tablets

Femara 2.5 Mg 30 Tablets

Description:

Femara 2.5 mg 30 tablets is a prescription oral anticancer medicine containing letrozole, a non-steroidal aromatase inhibitor used in the treatment of hormone receptor–positive breast cancer in postmenopausal women. It works by significantly reducing estrogen production in the body, helping to slow or stop the growth of estrogen-dependent breast tumors. Femara is commonly used as adjuvant, extended adjuvant, or first-line therapy in early and advanced breast cancer, and may also be used as pre-operative (neoadjuvant) treatment in selected patients under specialist supervision.

Indications:

• Treatment of hormone receptor–positive early breast cancer in postmenopausal women, usually after surgery and/or radiotherapy.
• Extended adjuvant treatment of early breast cancer in postmenopausal women who have completed standard adjuvant tamoxifen therapy.
• First-line treatment of hormone receptor–positive or hormone receptor–unknown locally advanced or metastatic breast cancer in postmenopausal women.
• Treatment of advanced breast cancer in natural or artificially induced postmenopausal women after relapse or disease progression following anti-estrogen therapy.
• Pre-operative (neoadjuvant) treatment in postmenopausal women with localized hormone receptor–positive breast cancer when immediate surgery is not suitable, as directed by an oncologist.

Active Ingredients / Key Components:

• Letrozole – 2.5 mg per film-coated tablet.
• Excipients (tablet core and coating) – may include lactose, cellulose derivatives, starch, and other pharmaceutical excipients (exact excipient list and concentrations , please check the product leaflet or the manufacturer’s official website; please refer to the official package insert).

Dosage & Administration / How to Use:

• Standard adult dose (postmenopausal women): 2.5 mg (one tablet) taken orally once daily, or exactly as prescribed by your oncologist.
• Femara tablets may be taken with or without food, preferably at the same time each day to maintain consistent blood levels.
• Swallow the tablet whole with a glass of water; do not crush, chew, or split unless advised by your healthcare provider.
• Treatment duration: often long term (months to years) depending on cancer stage, response, and treatment plan. Do not stop treatment unless instructed by your doctor.
• If you miss a dose and it is close to the time of your next dose, skip the missed dose and take the next dose at the regular time. Do not double the dose to make up for a missed tablet.
• Use only in postmenopausal women. It is not indicated for premenopausal women, pregnancy, or breastfeeding.
• Regular follow-up with your doctor is essential, including blood tests, liver function tests, bone density monitoring, and assessment of treatment response and side effects.

Clinical Benefits:

• Helps reduce estrogen levels by inhibiting the aromatase enzyme, slowing the growth of estrogen-dependent breast cancer cells.
• Improves disease-free survival and reduces the risk of breast cancer recurrence in postmenopausal women with hormone receptor–positive early breast cancer.
• Effective as first-line therapy in locally advanced or metastatic hormone receptor–positive breast cancer, helping to control tumor progression and associated symptoms.
• Provides an important treatment option for patients who have relapsed or progressed after previous anti-estrogen therapy such as tamoxifen.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to letrozole or any component of the formulation.
• Contraindicated in premenopausal women, during pregnancy, and during breastfeeding due to risk of harm to the fetus or infant.
• Use with caution in patients with moderate hepatic impairment; contraindicated or not recommended in severe hepatic impairment unless specifically directed and closely monitored by a specialist.
• May cause decreased bone mineral density and increase the risk of osteoporosis and fractures; baseline and periodic bone density assessment is recommended.
• May cause fatigue, dizziness, or somnolence; caution is advised when driving or operating machinery until you know how the medicine affects you.
• Use with caution in patients with a history of cardiovascular disease, hypercholesterolemia, or thromboembolic disorders; regular monitoring may be required.
• Consult your doctor before use if you have liver disease, kidney impairment, osteoporosis, low bone mineral density, high cholesterol, or any serious medical condition.
• Not intended to diagnose, treat, cure, or prevent any disease without medical supervision; it is a prescription anticancer medicine that must be used under the guidance of an oncologist.
• Keep out of reach of children.

Side Effects:

• Common side effects: hot flushes, sweating, fatigue, headache, dizziness, nausea, vomiting, diarrhea or constipation, weight gain, joint pain (arthralgia), muscle pain (myalgia), bone pain, and increased cholesterol levels.
• Other possible effects: mood changes, depression, insomnia, edema (swelling of hands, ankles, or feet), hair thinning, skin rash, and vaginal dryness.
• Long-term use may lead to decreased bone mineral density, osteopenia, or osteoporosis, with an increased risk of fractures.
• Serious side effects (seek immediate medical attention): signs of severe allergic reaction (swelling of face, lips, tongue, or throat; severe rash; difficulty breathing), severe chest pain, sudden shortness of breath, signs of stroke (sudden weakness, difficulty speaking, vision changes), or severe, persistent bone pain.
• Report any unusual or persistent symptoms to your doctor or pharmacist promptly.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed in its original blister or carton to protect from moisture. Keep out of reach of children. Do not use after the expiry date printed on the pack. Do not store above the temperature specified on the package insert (typically below 25–30 °c; refer to the official leaflet for exact storage conditions).

Specifications:

• Product type: prescription anticancer medicine (aromatase inhibitor).
• Active ingredient strength: letrozole 2.5 mg per film-coated tablet.
• Form: film-coated tablet for oral use.
• Pack size: 30 tablets per pack.
• Intended users: postmenopausal women under the supervision of an oncologist.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.